Company Quick10K Filing
Biorestorative Therapies
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 20 $5
10-Q 2019-11-13 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
S-1 2019-04-26 Public Filing
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-03-29 Annual: 2018-12-31
10-Q 2018-11-13 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-04-02 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-22 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-15 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-23 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
10-Q 2014-11-13 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
10-Q 2014-05-14 Quarter: 2014-03-31
10-K 2014-04-11 Annual: 2013-12-31
10-Q 2013-11-19 Quarter: 2013-09-30
10-Q 2013-08-19 Quarter: 2013-06-30
10-Q 2013-05-15 Quarter: 2013-03-31
10-K 2013-04-02 Annual: 2012-12-31
10-Q 2012-11-05 Quarter: 2012-09-30
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-14 Quarter: 2012-03-31
10-K 2012-04-16 Annual: 2011-12-31
10-Q 2011-11-21 Quarter: 2011-09-30
10-Q 2011-08-17 Quarter: 2011-06-30
8-K 2020-03-16 Enter Agreement, Bankruptcy, Off-BS Arrangement, Officers, Regulation FD, Exhibits
8-K 2020-02-28 Sale of Shares
8-K 2020-02-20 Sale of Shares
8-K 2020-02-20 Enter Agreement, Off-BS Arrangement, Sale of Shares, Officers, Exhibits
8-K 2020-02-13 Regulation FD
8-K 2020-02-11 Sale of Shares, Regulation FD, Off-BS Arrangement, Exhibits
8-K 2020-02-03 Sale of Shares, Regulation FD
8-K 2020-01-27 Sale of Shares
8-K 2020-01-20 Sale of Shares
8-K 2020-01-10 Sale of Shares, Officers
8-K 2020-01-08 Sale of Shares, Officers, Shareholder Vote, Exhibits
8-K 2019-12-31 Sale of Shares
8-K 2019-12-19 Enter Agreement, Sale of Shares
8-K 2019-12-12 Sale of Shares
8-K 2019-12-02 Sale of Shares
8-K 2019-11-20 Sale of Shares
8-K 2019-11-13 Shareholder Vote, Exhibits
8-K 2019-11-01 Leave Agreement
8-K 2019-10-30 Sale of Shares
8-K 2019-10-16
8-K 2019-10-07 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-09-30 Sale of Shares
8-K 2019-08-30 Shareholder Vote, Regulation FD, Sale of Shares, Exhibits
8-K 2019-08-21 Sale of Shares
8-K 2019-07-26 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-07-11 Sale of Shares
8-K 2019-06-18 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-06-06 Sale of Shares
8-K 2019-05-30 Shareholder Vote, Exhibits
8-K 2019-05-22 Sale of Shares
8-K 2019-05-07 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-04-30 Regulation FD, Exhibits
8-K 2019-04-18 Sale of Shares
8-K 2019-02-19 Enter Agreement, Sale of Shares, Exhibits
8-K 2019-02-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2019-01-22 Sale of Shares
8-K 2019-01-04 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-12-21 Sale of Shares
8-K 2018-12-13 Sale of Shares
8-K 2018-11-20 Enter Agreement
8-K 2018-10-28 Sale of Shares, Officers
8-K 2018-10-15 Enter Agreement, Officers, Exhibits
8-K 2018-10-04 Sale of Shares
8-K 2018-09-20 Sale of Shares
8-K 2018-09-06 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2018-08-31 Sale of Shares
8-K 2018-08-21 Shareholder Vote, Exhibits
8-K 2018-08-06 Sale of Shares
8-K 2018-06-27 Sale of Shares
8-K 2018-05-31 Regulation FD, Exhibits
8-K 2018-05-24 Regulation FD, Exhibits
8-K 2018-01-16 Officers, Regulation FD
8-K 2018-01-12 Sale of Shares

Biorestorative Therapies Financials

BRTX Metrics, Comps, Filings

Annual | Quarterly

Business

We were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware.

In January 2017, we submitted an Investigational New Drug application to the U.S. Food and Drug Administration, or the FDA, to obtain authorization to commence a Phase 2 clinical trial investigating the use of BRTX-100, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease. In February 2017, we received such authorization from the FDA.

In January 2019, a United States patent related to the ThermoStem Program was issued to us.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
E-Qure (EQUR) 4,836 -10.5 -1,247% 37 320 0 0 -457 -456 4,800
Sterling Consolidated (STCC) 4,728 28% 17.3 0% 7,036 5,715 5,486 1,516 31 272 4,695
Bespoke Extracts (BSPK) 4,689 -17% 1.6 3,249% 79 111 54 -9 2,581 2,938 4,679
Black Cactus Global (BLGI) 4,643 -1.2 -1,386% 286 916 0 0 -3,965 -3,900 4,601
Deep Well Oil & Gas (DWOG) 4,611 -21.7 -1% 22,677 527 0 0 -222 -211 4,577
Advantego (ADGO) 4,600 11% -5.2 -272% 554 4,782 29 3 -1,508 -858 4,465
Biorestorative Therapies (BRTX) 5,455 0% -0.4 -898% 1,458 13,887 98 0 -13,097 -12,936 5,514
Brightlane (BTLN) 4,486 75% -18.4 24,179,200% 83 63 -242 -242 4,449
Amplitech (AMPG) 2,417 51% 128.7 -0% 3,756 2,733 2,018 1,035 -11 25 3,211
Inception Mining (IMII) 4,755 -0.6 -369% 1,950 25,219 0 0 -7,192 -7,119 4,545
STR Holdings (STRI) 4,433 -59% -0.6 -29% 24,002 9,125 4,753 -2,786 -6,879 -7,185 4,557
Rodin Income Trust (RIT) 5,367 10.2 2% 26,379 15,997 0 0 460 460 4,682
Legacy Education Alliance (LEAI) 4,401 20% -6.1 4% 29,810 76,355 74,210 14,733 1,267 1,296 -7,896
Artemis Therapeutics (ATMS) 4,380 -38.4 -570% 20 256 0 0 -114 -114 4,377
Globe Photos (GBPT) 4,378 -0% -0.3 -64% 20,292 15,970 6,641 -4 -12,934 -12,874 4,070
Greenkraft (GKIT) 4,344 50% -128.4 -1% 2,476 4,931 944 469 -36 -36 4,672
OWC Pharmaceutical Research (OWCP) 0 0% -0.2 362% 1,773 1,467 100 0 6,420 6,420 -1,465
First Foods Group (FIFG) 4,422 30% -3.7 -228% 529 1,706 268 79 -1,204 -1,259 4,672
Wize Pharma (WIZP) 3,714 0% -0.9 -123% 2,091 2,238 2 0 -2,577 -2,577 2,229
True Nature Holding (TNTY) 1,496 -1.4 -263,898% 1 2,619 0 0 -2,246 -1,088 1,495

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Cash72020192146167322452118118
Accounts Receivable93620382929
Inventory121822
PP&E9559177494537643509417328175175
Assets2211,2681,3831,6921,8582,0171,5801,4241,7591,1921,192
Accounts Payable4267711,2701,1121,2662,5492,2842,4672,4551,8941,894
Long-Term Debt3,5945248383302298120194524524
Liabilities3,9076,4108,0688,5809,2535,9256,5807,1398,5959,8339,833
Stockholders' Equity-3,686-5,142-6,685-6,888-7,395-3,908-5,000-5,715-6,837-8,641-8,641
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Revenue01624166293681111111
Cost of Revenue1021426200
Gross Profit1412023673681
R&D124161,5941,4312,1052,8842,1521,5131,513
SG&A1,4771,3572,3802,3844,0393,3443,9694,3754,375
Tax000000
Net Income-4,074-6,537-5,751-5,588-7,923-8,636-9,445-12,518-12,518
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-03-312015-12-312016-12-312017-06-302017-12-312018-12-312018-12-31
Cash Operating-2,811-3,184-2,672-3,228-3,122-5,003-3,854-5,105-5,105
Cash Investing14-1,003-11-167-483-189-4-13-13
Cash Financing2,8504,1162,8843,2863,6805,0574,2774,7834,783